News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
5 year outcomes of SOC Axicabtagene Ciloleucel
Photo of Michael Jain from moffitt.org
Aug 5, 2024, 00:11

5 year outcomes of SOC Axicabtagene Ciloleucel

Graham Collins, Associate Professor of Haematology and lymphoma specialist at Oxford Cancer and Haematology centre, shared on X:

“5 year outcomes SOC Axi-Cel (Standard-of-Care Axicabtagene Ciloleucel): US real world data, Michael Jain et al.

• All 3rd+ line, 298 leucopheresed patients
• 5 year PFS/OS 29%/40%
• 5 year NRM (Non-Relapse Mortality) 16% (Infections/ 2nd malignancies dominant)
• NRM higher in > 60 year
Worrying NRM. Could this be lower when used 2nd line (less prior treatment)?”

Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

Authors: Michael D. Jain, Jay Y. Spiegel, Loretta J. Nastoupil, John Tamaresis, Armin Ghobadi, Yi Lin, Lazaros Lekakis, Patrick Reagan, Olalekan Oluwole, Joseph McGuirk, Abhinav Deol, Kathleen A. Dorritie, Alison R. Sehgal, Andre Goy, Brian T. Hill, Charalambos Andreadis, Javier Munoz, Matthew Ulrickson, Jason Westin, Julio C. Chavez, Dilan Patel, Miriam T. Jacobs, Radhika Bansal, N. Nora Bennani, Vivek G. Patel, Aaron P. Rapoport, Julie M. Vose, David B. Miklos, Sattva S. Neelapu, Frederick L. Locke, Matthew Lunning and Saurabh Dahiya.

5 year outcomes of SOC Axicabtagene Ciloleucel

Source: Graham Collins/X

Aaron P. Rapoport Abhinav Deol Alison R. Sehgal Andre Goy Armin Ghobadi Axicabtagene Ciloleucel Brian T. Hill cancer CAR T Consortium Charalambos Andreadis David B. Miklos Dilan Patel Frederick L. Locke Graham Collins Jason Westin Javier Munoz Jay Y. Spiegel John Tamaresis Joseph McGuirk Julie M. Vose Julio C. Chavez Kathleen A. Dorritie Large B-Cell Lymphoma Lazaros Lekakis Loretta J. Nastoupil Matthew Lunning Matthew Ulrickson Michael D. Jain Miriam T. Jacobs N. Nora Bennani non-relapse mortality Olalekan Oluwole OncoDaily Oncology Oxford Cancer and Haematology centre Patrick Reagan Radhika Bansal Sattva S. Neelapu Saurabh Dahiya Vivek G. Patel Yi Lin
Special Coverage
Blog
Jan 20, 2025, 04:32
Bevacizumab and carboplatin-pemetrexed chemotherapy with/out atezolizumab for advanced pleural mesothelioma
Blog
Jan 20, 2025, 04:29
Katsuaki Maehara: Lung EGFR mutations catalog
Opinion
Jan 20, 2025, 04:25
Elisabetta Bonzano: The identification and validation of patient-specific vulnerabilities
Blog
Jan 20, 2025, 04:21
Robin Zon: Behind every diagnosis, test, approval/ disapproval and outcome is a patient and their family
Insight
Jan 20, 2025, 04:14
Laura Bukavina discusses a paper on BCG treatment for patients with urothelial carcinoma of the prostatic urethra
Insight
Jan 20, 2025, 04:00
FDA approved datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer
Career
Jan 20, 2025, 03:10
Lawrence “Larry” Deist Appointed to Board of Directors at Rally Foundation for Childhood Cancer Research
Blog
Jan 20, 2025, 02:54
Drew Moghanaki: A new medical oncology position at the VA Medical Center in Long Beach
Science
Jan 20, 2025, 02:44
Assessment of fitness for bleomycin use and management of bleomycin pulmonary toxicity in patients with classical HL
Science
Jan 20, 2025, 02:16
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer
Blog
Jan 20, 2025, 02:14
Akriti Jain: Grateful to present at Cleveland Clinic ASH review
Career
Jan 19, 2025, 23:12
Kimryn Rathmell Steps Down as NCI Director, Concluding a Pivotal Leadership Era